ArticleParasites & vectors2025
Assessment of lotilaner (Credelio® CAT) for control of in-home Ctenocephalides felis infestations.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFlea infestations remain a major issue in veterinary medicine. Highly effective flea control for dogs and cats remains the foundation for eliminating infestations from homes and improving skin conditions associated with flea-feeding.
methodsHomes with pet cats were screened by flea-history questionnaire. Qualifying homes were subselected into "high" (≥ 5 fleas on ≥ 1 cat, and ≥ 5 fleas collected in environmental flea traps over a 16-24 h period), "low" (< 5 fleas on all cats, < 5 in traps), and "no" homes (no evidence of fleas on cats or traps). All cats and dogs in a household were treated with a lotilaner oral tablet (Credelio
resultsA total of 46 homes met inclusion criteria and completed the study: 19 "high" (35 cats); 17 "low" (27); and 10 "no" (14). By week 1, relative to pretreatment, there was a 99.3% reduction in flea counts on "high" cats, with 31 of 34 cats (91.2%) flea-free. By week 11-12, flea counts across all study cats and traps were zero. Prior to the first treatment, mean PVAS scores were: "high" 6.6; "low" 5.5; and "no" 1.9. By week 1 there was a significant decrease in mean PVAS score of cats from "high" homes to 2.9 (P < 0.0001), and mean week 11-12 scores were 0.5 and 0.8 for "high" and "low" homes, respectively. For SCORFAD, by week 11-12, relative to week 0, there was a significant decline in mean scores of cats from both "high" (8.0 to 1.7) (P < 0.0001) and "low" homes (3.3 to 0.9) (P < 0.0001).
conclusionsLotilaner was 100% efficacious in eliminating flea infestations from animals and their homes. The monthly lotilaner treatments of cats and dogs in flea-infested homes resulted in clinical resolution of pruritus and dermatologic lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.